• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突变等位基因频率对甲状腺癌组织病理学特征的影响

The Impact of Mutation Allele Frequency on the Histopathological Characteristics of Thyroid Cancer.

作者信息

Abdulhaleem Mawaddah, Bandargal Saruchi, Pusztaszeri Marc Philippe, Rajab Mohannad, Greenspoon Hannah, Krasner Joshua Ross, Da Silva Sabrina Daniela, Forest Véronique-Isabelle, Payne Richard J

机构信息

Department of Otolaryngology-Head and Neck Surgery, McGill University, Royal Victoria Hospital, Montreal, QC H4A 3J1, Canada.

Department of Otolaryngology-Head and Neck Surgery, McGill University, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.

出版信息

Cancers (Basel). 2023 Dec 25;16(1):113. doi: 10.3390/cancers16010113.

DOI:10.3390/cancers16010113
PMID:38201541
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10777954/
Abstract

BACKGROUND

A mutation in papillary thyroid cancer (PTC) has been shown to be associated with aggressive behavior. Nevertheless, not all PTCs behave aggressively. Allele frequency (AF) is the number of mutated molecules divided by the total number of wild-type molecules at a specific location in the genome. The relationship between AF and the histopathological features of thyroid malignancies is not well understood. We hypothesized that the AF will correlate directly with aggressive histopathological behavior. The aim of this study was to examine this relationship.

METHODS

A retrospective chart review was performed for patients treated for thyroid malignancies from 2019 to 2022 at McGill University tertiary care hospitals ( = 317). Patients with -positive malignancies that included information on AF were included ( = 44). The correlation between AF and tumor histopathological features was analyzed.

RESULTS

Out of the 44 nodules with a mutation, those with aggressive features of PTC had a mean AF of 25.8%, which was significantly higher than the non-aggressive group with a mean AF of 10.25% ( = 0.020). Additionally, there was a statistically significant difference in mean AF between patients with a positive sentinel LN (29%) and those with a negative sentinel LN (17.8%) ( = 0.021). Classical PTC was present in 29.5% (13/44) of nodules, with a mean AF of 15.6%. The tall cell subtype was found in 64% (28/44) of nodules, with a mean AF of 23%. Solid and hobnail subtypes were less common in this study, and there was no statistically significant relationship between AF and histopathological subtypes ( = 0.107). Nodules smaller than 1cm had a mean AF of 13.3%, while nodules ranging from 1 2cm had a mean AF of 20.6%, and those larger than 2cm had a mean AF of 27.7%. However, no statistical difference was observed between AF and nodule size ( = 0.160).

CONCLUSION

In this study, mutations in conjunction with AF help to determine whether thyroid malignancies will display aggressive behavior. This pre-operative finding can help thyroid specialists to determine the extent of thyroidectomy and whether lymph node dissection is required.

摘要

背景

甲状腺乳头状癌(PTC)中的一种突变已被证明与侵袭性行为有关。然而,并非所有PTC都具有侵袭性。等位基因频率(AF)是指在基因组特定位置上突变分子的数量除以野生型分子的总数。AF与甲状腺恶性肿瘤组织病理学特征之间的关系尚不清楚。我们假设AF将与侵袭性组织病理学行为直接相关。本研究的目的是检验这种关系。

方法

对2019年至2022年在麦吉尔大学三级护理医院接受甲状腺恶性肿瘤治疗的患者进行回顾性病历审查(n = 317)。纳入具有AF信息的BRAF阳性恶性肿瘤患者(n = 44)。分析AF与肿瘤组织病理学特征之间的相关性。

结果

在44个具有BRAF突变的结节中,具有PTC侵袭性特征的结节平均AF为25.8%,显著高于非侵袭性组,其平均AF为10.25%(P = 0.020)。此外,前哨淋巴结阳性患者(29%)与前哨淋巴结阴性患者(17.8%)的平均AF存在统计学显著差异(P = 0.021)。经典型PTC存在于29.5%(13/44)的结节中,平均AF为15.6%。高细胞亚型见于64%(28/44)的结节中,平均AF为23%。实性和鞋钉样亚型在本研究中较少见,AF与组织病理学亚型之间无统计学显著关系(P = 0.107)。小于1cm的结节平均AF为13.3%,而1 - 2cm的结节平均AF为20.6%,大于2cm的结节平均AF为27.7%。然而,AF与结节大小之间未观察到统计学差异(P = 0.160)。

结论

在本研究中,BRAF突变与AF共同有助于确定甲状腺恶性肿瘤是否会表现出侵袭性行为。这一术前发现有助于甲状腺专科医生确定甲状腺切除术的范围以及是否需要进行淋巴结清扫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1e7/10777954/916b7dd04af4/cancers-16-00113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1e7/10777954/4329d0a81dcc/cancers-16-00113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1e7/10777954/916b7dd04af4/cancers-16-00113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1e7/10777954/4329d0a81dcc/cancers-16-00113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1e7/10777954/916b7dd04af4/cancers-16-00113-g002.jpg

相似文献

1
The Impact of Mutation Allele Frequency on the Histopathological Characteristics of Thyroid Cancer.突变等位基因频率对甲状腺癌组织病理学特征的影响
Cancers (Basel). 2023 Dec 25;16(1):113. doi: 10.3390/cancers16010113.
2
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.BRAF V600E 突变与 ≤ 1.5 cm 的甲状腺乳头状癌的侵袭性特征相关。
J Otolaryngol Head Neck Surg. 2021 Nov 6;50(1):63. doi: 10.1186/s40463-021-00543-9.
3
Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.在预测高分化甲状腺癌侵袭性病理特征的存在方面,突变状态可能会取代肿瘤大小。
J Otolaryngol Head Neck Surg. 2022 Mar 4;51(1):9. doi: 10.1186/s40463-022-00559-9.
4
Molecular mutations as a possible factor for determining extent of thyroid surgery.分子突变作为决定甲状腺手术范围的一个可能因素。
J Otolaryngol Head Neck Surg. 2019 Oct 17;48(1):51. doi: 10.1186/s40463-019-0372-5.
5
A mutation panel comprising BRAF, NRAS, and NRAS replicated retrospective histopathological examination findings in differentiating benign goitre from malignant papillary thyroid cancer in a cohort of Malaysian patients.BRAF、NRAS 和 NRAS 突变panel 可复制回顾性组织病理学检查结果,有助于区分马来西亚患者队列中的良性甲状腺肿和恶性甲状腺乳头状癌。
Malays J Pathol. 2023 Dec;45(3):375-390.
6
Clinical significance of V600E mutation in 154 patients with thyroid nodules.154例甲状腺结节患者中V600E突变的临床意义
Oncol Lett. 2015 Jun;9(6):2633-2638. doi: 10.3892/ol.2015.3119. Epub 2015 Apr 15.
7
Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF mutation.根据甲状腺过氧化物酶抗体和 BRAF 突变的存在,弥漫性淋巴细胞浸润与甲状腺乳头状癌侵袭性的关系。
Head Neck. 2018 Oct;40(10):2271-2279. doi: 10.1002/hed.25327. Epub 2018 Jun 22.
8
Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.利用甲状腺乳头状癌残留的常规细针穿刺标本检测BRAF基因c.1799T > A(p.V600E)突变
Diagn Cytopathol. 2015 Oct;43(10):786-90. doi: 10.1002/dc.23302. Epub 2015 Jul 7.
9
BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.与其他基因事件相关的BRAF突变可识别侵袭性乳头状甲状腺癌的一个亚组。
Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. doi: 10.1111/j.1365-2265.2007.03077.x. Epub 2007 Dec 5.
10
Diagnostic Value and Challenges of BRAF V600E Molecular Testing and Thyroid Fine-Needle Aspiration Cytology: A Retrospective Study from a Tertiary Institution in Southern Hunan Province, China.中国湘南地区一家三级医院的回顾性研究:BRAF V600E 分子检测和甲状腺细针抽吸细胞学诊断价值及挑战
Acta Cytol. 2023;67(6):629-638. doi: 10.1159/000534138. Epub 2023 Sep 14.

引用本文的文献

1
Association Between Allele Frequency and Aggressive Behavior in Papillary Thyroid Microcarcinoma.甲状腺微小乳头状癌等位基因频率与侵袭性行为之间的关联
Cancers (Basel). 2025 Aug 1;17(15):2553. doi: 10.3390/cancers17152553.
2
Allele frequency in thyroid cancer: mechanisms, challenges, and applications in cancer therapy.甲状腺癌中的等位基因频率:机制、挑战及在癌症治疗中的应用
Thyroid Res. 2025 May 6;18(1):19. doi: 10.1186/s13044-025-00237-8.
3
NF-κB in Thyroid Cancer: An Update.NF-κB 在甲状腺癌中的作用:研究进展。

本文引用的文献

1
Performance of a Multigene Genomic Classifier in Thyroid Nodules with Suspicious for Malignancy Cytology.多基因基因组分类器在可疑恶性细胞学甲状腺结节中的性能。
Thyroid. 2022 Dec;32(12):1500-1508. doi: 10.1089/thy.2022.0282. Epub 2022 Sep 1.
2
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.低危甲状腺癌患者的甲状腺切除术不伴放射性碘治疗。
N Engl J Med. 2022 Mar 10;386(10):923-932. doi: 10.1056/NEJMoa2111953.
3
Genetic and Clinicopathologic Characteristics of Papillary Thyroid Carcinoma in the Chinese Population: High Mutation Allele Frequency, Multiple Driver Gene Mutations, and Fusion May Indicate More Advanced TN Stage.
Int J Mol Sci. 2024 Oct 25;25(21):11464. doi: 10.3390/ijms252111464.
4
Vitamin C in the Management of Thyroid Cancer: A Highway to New Treatment?维生素C在甲状腺癌治疗中的应用:通往新疗法之路?
Antioxidants (Basel). 2024 Oct 15;13(10):1242. doi: 10.3390/antiox13101242.
5
FHL1: A novel diagnostic marker for papillary thyroid carcinoma.FHL1:甲状腺乳头状癌的新型诊断标志物。
Pathol Int. 2024 Sep;74(9):520-529. doi: 10.1111/pin.13467. Epub 2024 Aug 9.
6
Drug repositioning in thyroid cancer: from point mutations to gene fusions.甲状腺癌中的药物重新定位:从点突变到基因融合
Front Oncol. 2024 May 8;14:1407511. doi: 10.3389/fonc.2024.1407511. eCollection 2024.
7
Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study.具有中高危复发风险的甲状腺乳头状癌中 BRAF V600E 和 TERT 突变的基因改变和等位基因频率:一项回顾性研究。
Clin Exp Med. 2024 Apr 12;24(1):76. doi: 10.1007/s10238-024-01320-4.
8
Advances in targeted therapy and biomarker research in thyroid cancer.甲状腺癌的靶向治疗和生物标志物研究进展。
Front Endocrinol (Lausanne). 2024 Mar 4;15:1372553. doi: 10.3389/fendo.2024.1372553. eCollection 2024.
中国人群甲状腺乳头状癌的遗传和临床病理特征:高突变等位基因频率、多个驱动基因突变和融合可能提示更高级别的TN分期。
Onco Targets Ther. 2022 Feb 9;15:147-157. doi: 10.2147/OTT.S339114. eCollection 2022.
4
Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review.对细胞学可疑和恶性(Bethesda V 和 VI)甲状腺结节进行分子检测,以优化手术干预的范围:一项回顾性图表回顾。
J Otolaryngol Head Neck Surg. 2021 Apr 28;50(1):29. doi: 10.1186/s40463-021-00500-6.
5
The influence of nodule size on the aggressiveness of thyroid carcinoma varies with patient's age.结节大小对甲状腺癌侵袭性的影响因患者年龄而异。
Gland Surg. 2021 Mar;10(3):961-972. doi: 10.21037/gs-20-747.
6
Molecular Genetics of Follicular-Derived Thyroid Cancer.滤泡源性甲状腺癌的分子遗传学
Cancers (Basel). 2021 Mar 7;13(5):1139. doi: 10.3390/cancers13051139.
7
BRAF V600E mutation correlates with aggressive clinico-pathological features but does not influence tumor recurrence in papillary thyroid carcinoma-10-year single-center results.BRAF V600E突变与侵袭性临床病理特征相关,但不影响甲状腺乳头状癌的肿瘤复发——单中心10年结果
Gland Surg. 2020 Dec;9(6):1902-1913. doi: 10.21037/gs-20-244.
8
Patient and tumor factors contributing to distant metastasis in well-differentiated thyroid cancer: a retrospective cohort study.影响分化型甲状腺癌远处转移的患者和肿瘤因素:一项回顾性队列研究。
J Otolaryngol Head Neck Surg. 2020 Nov 16;49(1):78. doi: 10.1186/s40463-020-00469-8.
9
Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review.甲状腺乳头状癌-侵袭性变异体及其对管理的影响:叙事性综述。
Adv Ther. 2020 Jul;37(7):3112-3128. doi: 10.1007/s12325-020-01391-1. Epub 2020 Jun 1.
10
The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting.在加拿大公共医疗保健环境中,甲状腺结节手术管理中 ThyroSeq v3 分子检测的作用。
Thyroid. 2020 Sep;30(9):1280-1287. doi: 10.1089/thy.2019.0539. Epub 2020 May 5.